Literature DB >> 32157571

Cholangiocarcinoma: State of the Art.

Bobak Moazzami1, Keivan Majidzadeh-A2, Arash Dooghaie-Moghadam1, Pegah Eslami3, Niloofar Razavi-Khorasani1, Shahrokh Iravani2, Alireza Khoshdel2, Farhad Shahi1, Habibolah Dashti1, Azim Mehrvar4, Mohssen Nassiri Toosi5.   

Abstract

BACKGROUND: Cholangiocarcinoma (CCA) is the second most frequent primary liver tumor and defined as the heterogeneous group of tumors derived from cells in the biliary tree. METHODS AND
RESULTS: Based on the anatomical locations (intrahepatic, perihilar, and distal), there are various approaches to the diagnosis and treatment of CCA. Imaging modalities, staging classifications, understandings around natural behavior of CCA, and therapeutic strategies have had remarkable progress in recent years.
CONCLUSIONS: This article reviews and discusses the epidemiology, clinical presentation, diagnosis, and treatment modalities of CCA; determines the appropriate inclusion and exclusion criteria for liver transplantation (LT); and defines the risk of disease progression for patients in the waiting list of LT.

Entities:  

Keywords:  Cholangiocarcinoma; Hepatectomy; Liver surgery; Liver transplantation; Neoadjuvant therapy

Mesh:

Substances:

Year:  2020        PMID: 32157571     DOI: 10.1007/s12029-020-00390-3

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  3 in total

1.  Intrahepatic cholangiocarcinoma in a non-cirrhotic liver in a patient with homozygous ZZ alpha-1 antitrypsin deficiency.

Authors:  Nienke E Vuurberg; Anne Loes Van den Boom; Marius C Van den Heuvel; Joost M Klaase
Journal:  BMJ Case Rep       Date:  2021-03-03

2.  Current Trends in Inpatient Care and In-Hospital Mortality of Cholangiocarcinoma in Germany: A Systematic Analysis between 2010 and 2019.

Authors:  Christoph Roderburg; Tobias Essing; Linde Kehmann; Sarah Krieg; Simon Labuhn; Jennis Kandler; Tom Luedde; Sven H Loosen
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575

3.  Transiently Elevated TC and sdLDL-C Levels and Falsely Low LDL-C Levels in Patients with Extrahepatic Cholangiocarcinoma.

Authors:  Yi Guo; Yong-Gen Zhang; Hong-Chun Li; Yin-Hai Xu
Journal:  Onco Targets Ther       Date:  2021-02-15       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.